Literature DB >> 17609872

Optimized conformal paraaortic lymph node irradiation is not associated with enhanced renal toxicity.

Meinhard Nevinny-Stickel1, Karin Poljanc, Britta C Forthuber, Dirk Heute, Andrea Posch, Judith Lechner, Beate Beer, Peter Lukas, Thomas Seppi.   

Abstract

BACKGROUND AND
PURPOSE: For patients with gynecologic carcinomas, irradiation of paraaortic lymph nodes (PLNs) is a routine treatment concept. Planning target volumes (PTVs) individually optimized by radiation field delineations along the big vessels permit the inclusion of at least 97% of potentially involved PLNs. However, this novel treatment technique might increase radiation-induced nephrotoxicity. Therefore, the actual incidence of kidney damage after PLN irradiation has to be assessed in order to validate the safety of this treatment concept. PATIENTS AND METHODS: 19 patients were treated with irradiation alone (50.4 Gy; 5 x 1.8 Gy/week) and monitored for up to 90 months. Functional renal parameters, namely renal plasma flow (RPF) and glomerular filtration rate (GFR), were assessed by dynamic renal scintigraphy. Additionally, patients were clinically observed (i.e., hypertension, proteinuria) and calculations of normal-tissue complication probability (NTCP) values for nonuniform kidney irradiation were performed using the Lyman-Wolbarst algorithm.
RESULTS: Two patients with anticipated moderate NTCP values (12.6% and 8.7%) showed slightly impaired RPF rates at 12, 24, and after 48 months of follow-up. Only one patient in the subgroup showing NTCP values > 50% (n = 9) developed a notable impairment of renal RPF. However, all patients including those with elevated complication probabilities exhibited neither impaired GFR nor clinically apparent symptoms related to a loss of functioning renal tissue from 12 to > 48 months post irradiation.
CONCLUSION: Conformal irradiation of retroperitoneal lymph nodes with individual PTV delineation appears not to be associated with clinically relevant functional impairment of the kidneys.

Entities:  

Mesh:

Year:  2007        PMID: 17609872     DOI: 10.1007/s00066-007-1657-6

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  6 in total

1.  Long-term outcome and prognostic factors in early-stage nodal low-grade non-hodgkin's lymphomas treated with radiation therapy.

Authors:  Hans Theodor Eich; Martina Heimann; Hartmut Stützer; Jan Kriz; Marcel Reiser; Rolf-Peter Müller
Journal:  Strahlenther Onkol       Date:  2009-05-15       Impact factor: 3.621

2.  Long-term renal toxicity in children following fractionated total-body irradiation (TBI) before allogeneic stem cell transplantation (SCT).

Authors:  Johanna Gerstein; Andreas Meyer; Karl-Walter Sykora; Jörg Frühauf; Johann H Karstens; Michael Bremer
Journal:  Strahlenther Onkol       Date:  2009-11-10       Impact factor: 3.621

3.  Dosimetric predictors of diarrhea during radiotherapy for prostate cancer.

Authors:  Giuseppe Sanguineti; Eugene J Endres; Maria Pia Sormani; Brent C Parker
Journal:  Strahlenther Onkol       Date:  2009-06-09       Impact factor: 3.621

4.  Long-term results of radiotherapy in primary carcinoma of the vagina.

Authors:  Stefan Hegemann; Ulrich Schäfer; Ralph Lellé; Normann Willich; Oliver Micke
Journal:  Strahlenther Onkol       Date:  2009-03-28       Impact factor: 3.621

Review 5.  Radiation-induced kidney toxicity: molecular and cellular pathogenesis.

Authors:  Richard Klaus; Maximilian Niyazi; Bärbel Lange-Sperandio
Journal:  Radiat Oncol       Date:  2021-02-25       Impact factor: 3.481

6.  Dose-Volume and Radiobiological Model-Based Comparative Evaluation of the Gastrointestinal Toxicity Risk of Photon and Proton Irradiation Plans in Localized Pancreatic Cancer Without Distant Metastasis.

Authors:  Vijay P Raturi; Taku Tochinai; Hidehiro Hojo; Toshiya Rachi; Kenji Hotta; Naoki Nakamura; Sadamoto Zenda; Atsushi Motegi; Takaki Ariji; Yasuhiro Hirano; Hiromi Baba; Hajime Ohyoshi; Masaki Nakamura; Masayuki Okumura; Yanping Bei; Tetsuo Akimoto
Journal:  Front Oncol       Date:  2020-10-23       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.